European Association of Dermato-Oncology (EADO) 16th European Post-Chicago Melanoma & Skin Cancer Meeting 2026 (Videos)

Comprehensive Updates in Melanoma, Non-Melanoma Skin Cancer, Dermato-Oncology, Immunotherapy, Dermoscopy, Gene Expression Profiling, Brain Metastases & Precision Skin Cancer Management

Stay at the forefront of skin cancer research and clinical practice with the European Association of Dermato-Oncology (EADO) 16th European Post-Chicago Melanoma & Skin Cancer Meeting 2026, one of Europe’s premier educational conferences dedicated to melanoma and cutaneous oncology. Organized under the auspices of the European Association of Dermato-Oncology (EADO) and the Melanoma World Society (MWS), this internationally recognized meeting brings together leading dermatologists, oncologists, surgeons, and researchers to review the most important scientific advances presented at ASCO 2026 and discuss their impact on everyday clinical practice.

Held June 25–26, 2026, at the Radisson Blu Hotel, Hamburg, Germany, this multidisciplinary conference delivers cutting-edge updates on melanoma biology, non-melanoma skin cancers, dermoscopy, immunotherapy, targeted therapy, gene expression profiling, radiation oncology, metastatic disease, and personalized treatment strategies. Through expert lectures, clinical trial reviews, evidence-based discussions, and international faculty presentations, participants gain practical knowledge that can immediately improve diagnostic accuracy, treatment selection, and long-term patient outcomes.

Designed for specialists involved in skin cancer diagnosis and management, the program emphasizes precision medicine, multidisciplinary collaboration, translational research, and implementation of the latest international guidelines.

Product Details

• Course: 16th European Post-Chicago Melanoma & Skin Cancer Meeting 2026
• Provider: European Association of Dermato-Oncology (EADO)
• In Collaboration With: Melanoma World Society (MWS)
• Conference Dates: June 25–26, 2026
• Location: Radisson Blu Hotel, Hamburg, Germany
• Format: Videos
• Language: English
• Educational Level: Advanced
• Learning Format: Expert Lectures, Clinical Trial Reviews, Guideline Updates, International Faculty Presentations, Case-Based Discussions

Course Overview

The management of melanoma and non-melanoma skin cancers continues to evolve rapidly with advances in immunotherapy, targeted therapies, molecular diagnostics, artificial intelligence, dermoscopy, gene expression profiling, and multidisciplinary oncology care. New evidence presented at major international meetings—including ASCO 2026—has significant implications for diagnosis, treatment sequencing, survivorship, and personalized medicine.

The 16th European Post-Chicago Melanoma & Skin Cancer Meeting 2026 provides a comprehensive review of these advances by bringing together internationally recognized experts who analyze the most important clinical trials, scientific discoveries, and guideline updates affecting contemporary dermato-oncology practice.

Participants gain practical insights into melanoma management, basal cell carcinoma, cutaneous squamous cell carcinoma, metastatic disease, brain metastases, immunotherapy optimization, biomarker development, and innovative therapeutic strategies that continue to redefine modern skin cancer care.

What You’ll Learn

After completing this course, participants will be able to:

• Interpret the most important melanoma and skin cancer updates presented at ASCO 2026.
• Apply dermoscopy to improve early detection of melanoma and non-melanoma skin cancers.
• Integrate lifestyle factors into comprehensive cancer management.
• Utilize melanoma registry data to improve clinical decision-making.
• Manage vulnerable patient populations including frail and immunocompromised individuals.
• Apply gene expression profiling (GEP) in melanoma risk assessment and treatment planning.
• Implement updated EADO recommendations for basal cell carcinoma and cutaneous squamous cell carcinoma.
• Evaluate emerging immunotherapies including ImmTACs and optimize management of metastatic melanoma.

Comprehensive Topics Covered

Melanoma

Master evidence-based diagnosis and management of melanoma.

Topics include:

• Cutaneous melanoma
• Melanoma staging
• Risk stratification
• Early diagnosis
• Surgical management
• Metastatic melanoma
• Personalized treatment

Faculty review the latest clinical evidence influencing melanoma care across all disease stages.

Non-Melanoma Skin Cancer

Strengthen management of the most common skin cancers.

Topics include:

• Basal cell carcinoma (BCC)
• Cutaneous squamous cell carcinoma (cSCC)
• High-risk skin cancers
• Surgical treatment
• Systemic therapy
• Radiation therapy
• Guideline-based care

Dermoscopy & Early Detection

Improve diagnostic accuracy through advanced skin imaging.

Topics include:

• Dermoscopy
• Pigmented lesions
• Skin cancer screening
• Early melanoma detection
• Diagnostic algorithms
• Clinical imaging
• Lesion recognition

Participants learn practical dermoscopic techniques that improve diagnostic confidence.

ASCO 2026 Clinical Trial Updates

Review practice-changing oncology research.

Topics include:

• ASCO 2026 highlights
• Landmark clinical trials
• Emerging evidence
• Treatment updates
• Translational research
• Precision oncology
• Clinical implementation

Immunotherapy & Targeted Therapy

Explore rapidly evolving systemic treatments.

Topics include:

• Immune checkpoint inhibitors
• PD-1 inhibitors
• CTLA-4 inhibitors
• Combination immunotherapy
• Targeted therapy
• Resistance mechanisms
• Treatment sequencing

Gene Expression Profiling & Precision Medicine

Integrate molecular diagnostics into melanoma care.

Topics include:

• Gene expression profiling (GEP)
• Molecular biomarkers
• Precision oncology
• Prognostic testing
• Risk prediction
• Personalized medicine
• Genomic diagnostics

Brain Metastases & Advanced Melanoma

Update management of complex metastatic disease.

Topics include:

• Melanoma brain metastases
• Central nervous system disease
• Neurosurgical management
• Stereotactic radiosurgery
• Systemic therapy
• Multidisciplinary care
• Survival optimization

Novel Immunotherapies

Review emerging therapeutic innovations.

Topics include:

• ImmTACs
• Bispecific therapies
• Immune modulation
• Advanced immunotherapy
• Novel biologics
• Future treatment strategies
• Clinical trial data

Radiotherapy & Multimodal Treatment

Strengthen multidisciplinary treatment planning.

Topics include:

• Adjuvant therapy
• Neoadjuvant therapy
• Radiotherapy
• Abscopal effect
• Combined modality treatment
• Local control
• Treatment optimization

Special Patient Populations

Optimize individualized skin cancer care.

Topics include:

• Frail patients
• Immunocompromised patients
• Pregnancy and family planning
• Elderly patients
• Survivorship
• Lifestyle medicine
• Exercise and nutrition

European Guidelines & Registry Updates

Stay current with international standards of care.

Topics include:

• EADO guidelines
• European melanoma registries
• Clinical databases
• Evidence-based recommendations
• Quality improvement
• Population studies
• International collaboration

Learning Objectives

Upon completion of this educational activity, participants will be able to:

• Evaluate the most important melanoma and non-melanoma skin cancer updates presented at ASCO 2026.
• Utilize dermoscopy for early detection and diagnosis of melanoma and other skin cancers.
• Assess the impact of lifestyle interventions—including nutrition, exercise, and timing of immune checkpoint inhibitor administration—on treatment outcomes.
• Interpret data from European melanoma registries and clinical databases.
• Optimize treatment for frail, immunocompromised, and family-planning patients with skin cancer.
• Apply gene expression profiling (GEP) and updated 2026 EADO guidelines to melanoma, basal cell carcinoma, and cutaneous squamous cell carcinoma management.
• Evaluate the role of ImmTACs and other emerging therapies for metastatic melanoma.
• Develop evidence-based strategies for melanoma brain metastases, radiotherapy integration, and adjuvant or neoadjuvant treatment.

Educational Highlights

• Melanoma
• Dermato-Oncology
• Non-Melanoma Skin Cancer
• Basal Cell Carcinoma (BCC)
• Cutaneous Squamous Cell Carcinoma (cSCC)
• Dermoscopy
• Gene Expression Profiling (GEP)
• Immunotherapy
• Immune Checkpoint Inhibitors
• ImmTAC Therapy
• Brain Metastases
• Radiation Oncology
• Precision Oncology
• Targeted Therapy
• ASCO 2026 Updates
• EADO Guidelines
• Melanoma Registries
• Multidisciplinary Oncology
• Skin Cancer Research
• Continuing Medical Education (CME)

Why This Course Stands Out

The European Association of Dermato-Oncology 16th European Post-Chicago Melanoma & Skin Cancer Meeting 2026 serves as one of Europe’s most influential educational meetings dedicated to melanoma and skin cancer. By translating the latest findings presented at ASCO into practical clinical recommendations, this conference enables participants to rapidly incorporate breakthrough therapies, updated guidelines, and precision oncology advances into patient care. Its multidisciplinary perspective, international faculty, and strong emphasis on evidence-based medicine make it an essential educational resource for clinicians managing both melanoma and non-melanoma skin cancers.

Target Audience

This educational activity is ideal for:

• Dermatologists
• Dermato-Oncologists
• Medical Oncologists
• Surgical Oncologists
• Radiation Oncologists
• Dermatologic Surgeons
• Plastic Surgeons involved in Skin Cancer Care
• Mohs Surgeons
• Pathologists with Dermatopathology Interest
• Oncology Fellows
• Dermatology Residents
• Oncology Nurse Practitioners
• Physician Assistants
• Healthcare Professionals involved in melanoma and skin cancer diagnosis, treatment, and research

Why Choose This Course?

Whether you specialize in dermatology, medical oncology, surgical oncology, radiation oncology, or multidisciplinary skin cancer care, the EADO 16th European Post-Chicago Melanoma & Skin Cancer Meeting 2026 provides one of the most comprehensive reviews of contemporary dermato-oncology available. Through internationally recognized faculty, ASCO 2026 updates, evidence-based discussions, guideline reviews, and practical clinical insights, participants gain the knowledge needed to optimize melanoma diagnosis, personalize treatment strategies, integrate novel immunotherapies, and improve outcomes for patients with skin cancer.

Topics

• SYMPOSIUM I: My personal highlights at ASCO 2026

  • in melanoma

  • in non-melanoma skin cancer

• KEYNOTE LECTURE I: Dermoscopy for the detection of all skin cancers?!

• SYMPOSIUM II: Lifestyle factors impacting cancer treatment outcomes

  • Exercise

  • Nutrition

  • Timing of ICI administration

• SYMPOSIUM III: Merkel Cell Carcinoma

  • Adjuvant and neoadjuvant trials

  • Role of irradiation for MCC

  • Treatment for advanced MCC

• SYMPOSIUM IV: Treatment of vulnerable skin cancer patients

  • Family planning

  • Old and frail patients

  • Immunocompromised patients

• SYMPOSIUM V: Adverse event management for ICI

  • Long-term toxicities / delayed onset toxicities

  • ICI rechallenge after immune-related adverse events

  • What you should know about differences of various immunosuppressants

• SYMPOSIUM VI: GEP – Gene expression profiling

  • Which test is the best for melanoma?

  • What can we learn from Breast Cancer (Oncotype DX Test)?

  • How to implement GEP in melanoma guidelines?

• SYMPOSIUM VII: EADO guidelines 2026 for various skin cancers: What’s new?

  • …basal cell carcinoma (BCC)

  • …cutaneous squamous cell carcinoma (CSCC)

  • …current trials for BCC/CSCC with future implications

• SYMPOSIUM VIII: ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas

  • Treatment of metastatic ocular melanoma: it’s a whole new world!

  • Tebentafusp, Brenetafusp and other ImmTACs not only for uveal melanoma

• KEYNOTE LECTURE II: Personalized oncology: already reality or just a dream?

• KEYNOTE LECTURE III: Neoadjuvant or perioperative treatment for melanoma?

• SYMPOSIUM IX: Is the abscopal effect of radiotherapy existing? (Yes / No Panel Discussion)

• SYMPOSIUM X: Adjuvant treatment of melanoma

  • Targeted therapy or immune checkpoint inhibition for BRAF mutated stage III patients?

  • Is combo immune checkpoint inhibition replacing single agent anti-PD1?

  • How long is long enough?

• Satellite Symposia:

  • Nuances in Metastatic Uveal Melanoma Care A Global Dialogue on current Clinical Practice, Treatment Algorithms and Emerging Insights

  • Advancing Treatment Pathways in Cutaneous Squamous Cell Carcinoma: Patients to Practice

  • Early-Stage Melanoma in Daily Practice: Are We Ready for Individualized Therapy?

  • Redefining Melanoma Care 2026: Innovation, Evidence, Outcomes

  • Immune checkpoint inhibitors in Merkel cell carcinoma: 10 years of progress from 2016 to 2026